



5 September 2017

## **All Three Canada House Wholly Owned Subsidiaries Have Recently Reached Important Goals**

*Toronto September 5, 2017.* Canada House Wellness Group Inc. (CSE: CHV) (“**Canada House**” or the “**Company**”) is pleased to announce that all three of its wholly-owned subsidiaries, Marijuana for Trauma “MFT”, Knalysis Technologies “Knalysis” and Abba Medix “Abba”, have reached important goals.

**Marijuana for Trauma, which fully implemented its web-based CPM client intake processes in July**, now reports that it has achieved its interim goal of processing more than 750 clients during August. MFT radio advertisements will begin running in the Ottawa and GTA this week. These ads, combined with FREE and timely access to prescribers across Ontario, should drive MFT’s next intake goal of 1,000 new clients a month, which it expects to accomplish by October. Every client processed in the past 60 days met with one of MFT’s highly trained Cannabinoid Therapy Educators (CTEs), adding further value to MFT’s client experience.

**Our Knalysis Technologies subsidiary has recently secured its first US-based clients**, in several US states, for both its web-based Cannabis Patient Management “CPM” software and its Analytics Web Portal “AWP” platform which tracks the efficacy of medical cannabis on the treatment of symptoms using our free Knalysis Wellness Tracker® smartphone app. We are excited to partner with forward thinking clients who are committed to finding the right treatments and offer informed recommendations for their patients.

Knalysis’ proprietary data structure allows it to quantify patient treatment data and provides visibility for growers, clinics, practitioners and patients to how well treatments are working. With the benefit of this data, Knalysis expects to be publishing a suite of cannabis industry reports commencing before the end of this year.

And, of course, **our Abba Medix subsidiary received just last Friday its Health Canada License to Cultivate under the ACMPR**. Focussed action will continue to be taken as Abba’s management now set their sights on obtaining the Health Canada License to Sell under the ACMPR. Further development of the Abba facility will continue in parallel to our commencement of plant propagation with the goal of being in full production at the time of receiving a License to Sell. This week Abba will complete its application for its ‘Import Permit for Seeds’, as per ACMPR regulations. Abba management will be very selective in choosing its cannabis strains, to satisfy the most discriminating customers, including, of course, those clients of MFT.

### **Canada House Wellness Group Inc.**

*Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit <http://www.canadahouse.ca>. or [www.sedar.com](http://www.sedar.com)*

**For further information, please contact:**

Boom Capital Markets

Steve Low

647-620-5101

[steve@boomcapitalmarkets.com](mailto:steve@boomcapitalmarkets.com)

***Cautionary Statement Regarding Forward-Looking Information.** Certain statements within this news release pertaining to the Company constitute “forward-looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward-looking statements”. Such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.*

*Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.*